1. Home
  2. GAM vs TSHA Comparison

GAM vs TSHA Comparison

Compare GAM & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo General American Investors Inc.

GAM

General American Investors Inc.

HOLD

Current Price

$63.98

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.84

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAM
TSHA
Founded
1927
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
GAM
TSHA
Price
$63.98
$6.84
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$11.63
AVG Volume (30 Days)
21.8K
2.6M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
5.74%
N/A
EPS Growth
N/A
5.56
EPS
11.67
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,152.42
P/E Ratio
$5.54
N/A
Revenue Growth
N/A
17.28
52 Week Low
$52.69
$2.25
52 Week High
$66.18
$7.30

Technical Indicators

Market Signals
Indicator
GAM
TSHA
Relative Strength Index (RSI) 55.05 65.99
Support Level $62.61 $4.39
Resistance Level $64.28 N/A
Average True Range (ATR) 1.20 0.41
MACD -0.19 -0.02
Stochastic Oscillator 23.88 59.24

Price Performance

Historical Comparison
GAM
TSHA

About GAM General American Investors Inc.

General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations. The company invests principally in common stocks believed by management to have growth potential.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: